ATE339223T1 - Kombinierte impfstoffzusammensetzungen - Google Patents

Kombinierte impfstoffzusammensetzungen

Info

Publication number: ATE339223T1
Authority: AT; Austria
Prior art keywords: vaccine compositions; combined vaccine; combined; compositions; vaccine
Prior art date: 1998-03-09

Application number

AT99914473T

Other languages

English (en)

Inventor

Jean Stephenne

Martine Anne Cecil Wettendorff

Original Assignee

Glaxosmithkline Biolog Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-09

Filing date

1999-03-04

Publication date

2006-10-15

1998-03-09 Priority claimed from GBGB9805105.5A external-priority patent/GB9805105D0/en

1998-06-23 Priority claimed from GBGB9813561.9A external-priority patent/GB9813561D0/en

1999-03-04 Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa

2006-10-15 Application granted granted Critical

2006-10-15 Publication of ATE339223T1 publication Critical patent/ATE339223T1/de

Links

239000000203 mixture Substances 0.000 title 1
229960005486 vaccine Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/826—Viruses

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Mycology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Dermatology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AT99914473T 1998-03-09 1999-03-04 Kombinierte impfstoffzusammensetzungen ATE339223T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9805105.5A GB9805105D0 (en)	1998-03-09	1998-03-09	Novel composition
GBGB9813561.9A GB9813561D0 (en)	1998-06-23	1998-06-23	Novel composition

Publications (1)

Publication Number	Publication Date
ATE339223T1 true ATE339223T1 (de)	2006-10-15

Family

ID=26313263

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99914473T ATE339223T1 (de)	1998-03-09	1999-03-04	Kombinierte impfstoffzusammensetzungen

Country Status (22)

Country	Link
US (2)	US6451320B1 (de)
EP (1)	EP1064025B1 (de)
JP (1)	JP4510283B2 (de)
KR (1)	KR20010041629A (de)
CN (1)	CN1299288A (de)
AR (1)	AR014684A1 (de)
AT (1)	ATE339223T1 (de)
AU (1)	AU750720B2 (de)
BR (1)	BR9908599A (de)
CA (1)	CA2324289C (de)
CO (1)	CO4960659A1 (de)
DE (1)	DE69933200T2 (de)
ES (1)	ES2273482T3 (de)
HU (1)	HUP0101047A3 (de)
IL (1)	IL137998A0 (de)
MY (1)	MY135965A (de)
NO (1)	NO20004487L (de)
NZ (1)	NZ506602A (de)
PL (1)	PL343429A1 (de)
TR (1)	TR200002608T2 (de)
TW (1)	TW580393B (de)
WO (1)	WO1999045957A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5849719A (en) *	1993-08-26	1998-12-15	The Regents Of The University Of California	Method for treating allergic lung disease
US20030078223A1 (en) *	1996-01-30	2003-04-24	Eyal Raz	Compositions and methods for modulating an immune response
ES2284287T3 (es)	1998-10-16	2007-11-01	Glaxosmithkline Biologicals S.A.	Sistemas adyuvantes y vacunas.
CZ20012544A3 (cs) *	1999-01-12	2002-01-16	Smithkline Beecham Biologicals S.A.	Farmaceutické balení
US20050002958A1 (en) *	1999-06-29	2005-01-06	Smithkline Beecham Biologicals Sa	Vaccines
GB9921146D0 (en)	1999-09-07	1999-11-10	Smithkline Beecham Biolog	Novel composition
AU2003236490B2 (en) *	1999-09-07	2004-08-19	Smithkline Beecham Biologicals S.A.	Novel composition
GB9921147D0 (en) *	1999-09-07	1999-11-10	Smithkline Beecham Biolog	Novel composition
SI1650221T1 (sl) *	2000-02-23	2012-09-28	Glaxosmithkline Biolog Sa	Nove spojine
US7811574B2 (en)	2000-02-23	2010-10-12	Glaxosmithkline Biologicals S.A.	Tumour-specific animal proteins
GB0019728D0 (en) *	2000-08-10	2000-09-27	Smithkline Beecham Biolog	Novel treatment
UA79735C2 (uk)	2000-08-10	2007-07-25	Глаксосмітклайн Байолоджікалз С.А.	Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
KR20050048539A (ko) *	2001-10-06	2005-05-24	메리얼엘엘씨	ＣｐＧ 제제 및 관련된 방법
GB0206359D0 (en)	2002-03-18	2002-05-01	Glaxosmithkline Biolog Sa	Viral antigens
GB0206360D0 (en)	2002-03-18	2002-05-01	Glaxosmithkline Biolog Sa	Viral antigens
GB0210682D0 (en) *	2002-05-09	2002-06-19	Glaxosmithkline Biolog Sa	Novel use
KR100525321B1 (ko) *	2002-12-13	2005-11-02	안웅식	파필로마바이러스 항원 단백질 및ＣｐＧ-올리고데옥시뉴클레오타이드를 포함하는파필로마바이러스 유발 질환의 예방 또는 치료용 약제학적조성물
US7858098B2 (en)	2002-12-20	2010-12-28	Glaxosmithkline Biologicals, S.A.	Vaccine
CN1513555A (zh) *	2003-07-31	2004-07-21	长春生物制品研究所	甲-乙型肝炎联合疫苗及其冻干制剂
US20120027841A1 (en) *	2004-01-07	2012-02-02	Biomedical Research Models, Inc.	Novel mucosal vaccination approach for herpes simplex virus type-2
US7758866B2 (en)	2004-06-16	2010-07-20	Glaxosmithkline Biologicals, S.A.	Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
DK1861120T3 (en) *	2005-03-23	2016-07-25	Glaxosmithkline Biologicals Sa	Use of an influenza virus and an oil-in-water emulsion adjuvant to induce CD 4 T cell and / or enhanced B memory cell response
EP2059255A4 (de) *	2006-09-08	2011-08-31	Univ Pennsylvania	Hsv-1- und hsv-2-impfstoffe sowie verfahren zu ihrer anwendung
US8865185B2 (en)	2006-09-08	2014-10-21	The Trustees Of The University Of Pennsylvania	Methods of use for HSV-1 and HSV-2 vaccines
EP2468300B1 (de)	2006-09-26	2017-12-20	Infectious Disease Research Institute	Impfstoffzusammensetzung mit einem synthetischen Adjuvans
US20090181078A1 (en)	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
US8057804B2 (en) *	2006-12-28	2011-11-15	The Trustees Of The University Of Pennsylvania	Herpes simplex virus combined subunit vaccines and methods of use thereof
US10478490B2 (en)	2006-12-28	2019-11-19	The Trustees Of The University Of Pennsylvania	Herpes simplex virus combined subunit vaccines and methods of use thereof
US9284355B2 (en) *	2006-12-28	2016-03-15	The Trustees Of The University Of Pennsylvania	Herpes simplex virus combined subunit vaccines and methods of use thereof
BRPI0909547A2 (pt) *	2008-05-26	2019-03-06	Cadila Healthcare Ltd.	vacina combinada de sarampo - hpv, vetor e hospedero
RU2585961C9 (ru) *	2009-05-22	2016-12-27	Дженосеа Биосайенсиз Инк.	Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
AU2010252012A1 (en)	2009-05-27	2011-12-22	Glaxosmithkline Biologicals S.A.	CASB7439 constructs
CA2764374C (en)	2009-06-05	2019-11-19	Infectious Disease Research Institute	Synthetic glucopyranosyl lipid adjuvants
CN107029223A (zh) *	2010-05-26	2017-08-11	西莱克塔生物科技公司	合成纳米载体联合疫苗
JP6055776B2 (ja)	2010-11-24	2016-12-27	ジェノセアバイオサイエンシーズ，インコーポレイテッド	単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法
NZ616304A (en)	2011-04-08	2016-01-29	Immune Design Corp	Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN102210858B (zh) *	2011-05-18	2013-05-08	北京科兴生物制品有限公司	一种肠道病毒71型与甲型肝炎联合疫苗
EP2726097A4 (de)	2011-07-01	2015-03-11	Univ California	Herpes-virus-impfstoff und verwendungsverfahren
JP6199878B2 (ja)	2011-11-23	2017-09-20	ジェノセアバイオサイエンシーズ，インコーポレイテッド	単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法
PL2811981T3 (pl)	2012-02-07	2019-09-30	Infectious Disease Research Institute	Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
SMT201800368T1 (it)	2012-05-16	2018-09-13	Immune Design Corp	Vaccini per l'infezione da virus-2 herpes simplex
EP2941269B1 (de)	2013-01-07	2020-12-09	Mucosal Vaccine Technologies LLC	Therapeutische impfstoffe zur behandlung von herpes-simplex-virus-typ 2-infektionen
CA2909221A1 (en)	2013-04-18	2014-10-23	Immune Design Corp.	Gla monotherapy for use in cancer treatment
US9463198B2 (en)	2013-06-04	2016-10-11	Infectious Disease Research Institute	Compositions and methods for reducing or preventing metastasis
IL310015B2 (en)	2013-12-31	2026-02-01	Access To Advanced Health Inst	Single vial formulation
EP3519427A4 (de)	2016-09-28	2020-03-11	Genocea Biosciences Inc.	Verfahren und zusammensetzungen zur behandlung von herpes
CN107987159B (zh) *	2017-11-28	2021-06-22	上海药明生物医药有限公司	一种使用大剂量dna免疫技术免疫动物使血清中抗体滴度提高的方法
BR112021023726A2 (pt)	2019-05-25	2022-02-15	Infectious Disease Res Inst	Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
EP4058581A1 (de)	2019-11-15	2022-09-21	Infectious Disease Research Institute	Rig-i-agonist und adjuvans-formulierung zur tumorbehandlung

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1678783A (en) *	1982-07-20	1984-01-26	Molecular Genetics, Inc.	Production of herpes simplex viral proteins
JPH085804B2 (ja) *	1988-04-28	1996-01-24	財団法人化学及血清療法研究所	Ａ型及びｂ型肝炎混合アジュバントワクチン
CA2088600C (en) *	1990-08-02	1999-11-16	Rae L. Burke	Herpes simplex virus vp16 vaccines
EP0563091A1 (de) *	1990-12-20	1993-10-06	SMITHKLINE BEECHAM BIOLOGICALS s.a.	Impfstoffe auf basis hepatitis-b-oberflächenantigen
JP3026029B2 (ja) *	1991-04-26	2000-03-27	財団法人阪大微生物病研究会	組換え水痘ウイルスとその作製法
MY111880A (en) *	1992-03-27	2001-02-28	Smithkline Beecham Biologicals S A	Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
JP3626996B2 (ja) *	1992-05-23	2005-03-09	グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム	Ｂ型肝炎表面抗原および他の抗原からなる複合ワクチン
EP0609739A1 (de) *	1993-02-02	1994-08-10	American Cyanamid Company	Methode der Umkehrung der Immunsuppression in Vakzinen
GB9326253D0 (en) *	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
GB9409962D0 (en) *	1994-05-18	1994-07-06	Smithkline Beecham Biolog	Novel compounds
AUPN015794A0 (en) *	1994-12-20	1995-01-19	Csl Limited	Variants of human papilloma virus antigens
ES2301175T3 (es) *	1996-02-09	2008-06-16	Smithkline Beecham Biologicals S.A.	Vacunas contra el producto del gen 63 del virus de la varicela zoster.

1999
- 1999-03-04 TR TR2000/02608T patent/TR200002608T2/xx unknown
- 1999-03-04 JP JP2000535370A patent/JP4510283B2/ja not_active Expired - Fee Related
- 1999-03-04 KR KR1020007009828A patent/KR20010041629A/ko not_active Ceased
- 1999-03-04 CA CA2324289A patent/CA2324289C/en not_active Expired - Fee Related
- 1999-03-04 CN CN99805849A patent/CN1299288A/zh active Pending
- 1999-03-04 NZ NZ506602A patent/NZ506602A/xx unknown
- 1999-03-04 AU AU33283/99A patent/AU750720B2/en not_active Ceased
- 1999-03-04 PL PL99343429A patent/PL343429A1/xx unknown
- 1999-03-04 US US09/623,708 patent/US6451320B1/en not_active Expired - Lifetime
- 1999-03-04 ES ES99914473T patent/ES2273482T3/es not_active Expired - Lifetime
- 1999-03-04 IL IL13799899A patent/IL137998A0/xx unknown
- 1999-03-04 BR BR9908599-2A patent/BR9908599A/pt not_active IP Right Cessation
- 1999-03-04 AT AT99914473T patent/ATE339223T1/de not_active IP Right Cessation
- 1999-03-04 EP EP99914473A patent/EP1064025B1/de not_active Expired - Lifetime
- 1999-03-04 HU HU0101047A patent/HUP0101047A3/hu unknown
- 1999-03-04 DE DE69933200T patent/DE69933200T2/de not_active Expired - Lifetime
- 1999-03-04 WO PCT/EP1999/001406 patent/WO1999045957A2/en not_active Ceased
- 1999-03-05 MY MYPI99000825A patent/MY135965A/en unknown
- 1999-03-05 AR ARP990100970A patent/AR014684A1/es unknown
- 1999-03-09 CO CO99014298A patent/CO4960659A1/es unknown
- 1999-03-09 TW TW088103595A patent/TW580393B/zh not_active IP Right Cessation
2000
- 2000-09-08 NO NO20004487A patent/NO20004487L/no not_active Application Discontinuation
2002
- 2002-08-23 US US10/226,798 patent/US6932972B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20030129199A1 (en)	2003-07-10
US6932972B2 (en)	2005-08-23
WO1999045957A3 (en)	1999-11-25
AU750720B2 (en)	2002-07-25
PL343429A1 (en)	2001-08-13
DE69933200T2 (de)	2007-02-22
CN1299288A (zh)	2001-06-13
IL137998A0 (en)	2001-10-31
JP4510283B2 (ja)	2010-07-21
HUP0101047A3 (en)	2004-10-28
EP1064025A2 (de)	2001-01-03
TR200002608T2 (tr)	2000-11-21
CA2324289A1 (en)	1999-09-16
NZ506602A (en)	2003-02-28
ES2273482T3 (es)	2007-05-01
WO1999045957A2 (en)	1999-09-16
HUP0101047A1 (hu)	2001-07-30
AR014684A1 (es)	2001-03-28
AU3328399A (en)	1999-09-27
NO20004487L (no)	2000-10-19
BR9908599A (pt)	2000-11-14
CO4960659A1 (es)	2000-09-25
MY135965A (en)	2008-07-31
EP1064025B1 (de)	2006-09-13
TW580393B (en)	2004-03-21
DE69933200D1 (de)	2006-10-26
JP2002506045A (ja)	2002-02-26
NO20004487D0 (no)	2000-09-08
KR20010041629A (ko)	2001-05-25
US6451320B1 (en)	2002-09-17
CA2324289C (en)	2010-07-13

Legal Events

Date	Code	Title	Description
2007-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69933200D1 (de)	2006-10-26	Kombinierte impfstoffzusammensetzungen
NO20004758L (no)	2000-11-08	Vaksinesammensetning
DE60027029D1 (de)	2006-05-18	Kombinierte impfstoffzusammensetzungen
ATE490327T1 (de)	2010-12-15	Impfstoffzusammensetzung
ID26549A (id)	2001-01-18	Komposisi-komposisi epotilon
ATE367793T1 (de)	2007-08-15	Schweisshemmende zusammensetzungen
IS5555A (is)	2000-06-30	Selekoxib lyfjablöndur
ID30031A (id)	2001-11-01	Formulasi-formulasi agrokimia
ID23546A (id)	2000-05-04	Formulasi-formulasi ziprasidon
AR023440A1 (es)	2002-09-04	Composiciones antitranspirantes
NO20004240D0 (no)	2000-08-24	Formuleringer
ATE224703T1 (de)	2002-10-15	Brauseformulierungen
DE69900634D1 (de)	2002-01-31	Shampoozusammensetzungen
FI981011L (fi)	1999-11-07	Uudet koostumukset
ATE469550T1 (de)	2010-06-15	Antiparasitäre zusammensetzungen
EA199900373A3 (ru)	2000-08-28	Фармацевтические композиции
NO20006191D0 (no)	2000-12-06	Vaksine
DE69935172D1 (de)	2007-03-29	Imidosilan Zusammensetzungen
ID29785A (id)	2001-10-11	Komposisi-komposisi sampo
ATE257691T1 (de)	2004-01-15	Schweisshemmende zusammensetzungen
ID27889A (id)	2001-05-03	Komposisi-komposisi kopolimer polisiklik
IS6398A (is)	2002-05-27	Lyfjablöndur
NO20005599D0 (no)	2000-11-06	Vaksine
EE200100168A (et)	2002-06-17	Immunogeensed liposoomikompositsioonid
IS5569A (is)	2000-07-20	Lyfjasamsetningar